The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients. Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per 100,000, and which is more dominant in those of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!